What Autoimmune Gastritis Actually Is

Autoimmune gastritis — also called Type A gastritis, autoimmune metaplastic atrophic gastritis, or corpus-restricted atrophic gastritis — is an organ-specific autoimmune disease in which the body's own immune system mounts a sustained attack on the acid-producing parietal cells of the stomach. Over years to decades, this attack hollows out the glandular lining of the stomach's body and dome, leaving a thinned, atrophic mucosa that can no longer make stomach acid or the protein required to absorb vitamin B12.

The geography of the disease is one of its defining features. Autoimmune gastritis is corpus-and-fundus restricted — it targets the upper two-thirds of the stomach (the corpus, or body, and the fundus, or dome) where parietal cells live, while characteristically sparing the antrum, the lower portion. This distribution is the mirror image of Helicobacter pylori-driven (Type B) gastritis, which tends to begin in the antrum. That distinction is not academic: it shapes the antibody profile, the hormone consequences, the cancer risk, and the entire clinical story.

This page is an education-first resource. Autoimmune gastritis is a serious, lifelong condition that demands a gastroenterologist, endoscopic surveillance, and — once pernicious anemia develops — permanent B12 replacement. Nothing here substitutes for that care. As you will read repeatedly and emphatically, the single most dangerous misunderstanding a person with this disease can have is the belief that any food, including sea moss, can supply the B12 their stomach can no longer absorb. It cannot. What this page can do is walk through the biology honestly, then show exactly where the nutrients in sea moss intersect — and where they emphatically do not.

The Autoimmune Engine: CD4+ T Cells vs. the Proton Pump

At the molecular heart of autoimmune gastritis is a battle over a single enzyme: the gastric H+/K+-ATPase, better known as the proton pump. This pump is the machine parietal cells use to secrete hydrochloric acid, pushing hydrogen ions into the stomach in exchange for potassium. It is also the principal autoantigen of the disease.

The demolition is driven primarily by autoreactive CD4+ T helper cells — specifically Th1-skewed cells producing interferon-gamma (IFN-γ) — that recognize the alpha and beta subunits of the H+/K+-ATPase and orchestrate the destruction of parietal cells in the corpus and fundus. This is fundamentally a cell-mediated disease; the antibodies are markers of the process more than its primary weapon. Mouse models elegantly demonstrate that CD4+ T cells specific for the proton pump are both necessary and sufficient to cause the disease.

The two antibodies that tell the story

Two autoantibodies define the serology, and the distinction between them matters enormously for diagnosis:

• Anti-parietal cell antibodies (APCA, also called anti-H+/K+-ATPase antibodies): Directed against the proton pump itself, these are present in roughly 90% of patients at diagnosis — high sensitivity. The catch is low specificity: they also appear in many people with other autoimmune conditions (such as Hashimoto's thyroiditis and type 1 diabetes) and even in a meaningful fraction of healthy older adults. A positive APCA raises suspicion but does not, by itself, confirm the disease.
• Anti-intrinsic factor antibodies (AIF): Far less sensitive (positive in only 30–50%) but much more specific for pernicious anemia. There are two functional types — Type I (blocking) antibodies prevent B12 from binding to intrinsic factor, while Type II (binding) antibodies attach to the intrinsic factor–B12 complex and stop it from being absorbed at the ileum. A positive AIF is close to a clinching finding for pernicious anemia.

From proton pump to achlorhydria

As parietal cells are destroyed, two of their critical products vanish. First goes hydrochloric acid: the loss of functioning H+/K+-ATPase produces progressive hypochlorhydria and ultimately achlorhydria — a stomach that makes essentially no acid. Second goes intrinsic factor (IF), the glycoprotein parietal cells secrete that is absolutely required for B12 absorption in the terminal ileum. The collapse of these two functions sets off the entire downstream clinical cascade.

Genetics, metaplasia and the road to cancer

Genetic susceptibility shapes who develops the disease, with associations to the HLA class II haplotypes HLA-DR3 and HLA-DR4 — the same broad immunogenetic neighborhood shared by many organ-specific autoimmune diseases. As the corpus mucosa is destroyed, the stomach attempts to heal through abnormal repair pathways. Chief cells give rise to SPEM (spasmolytic polypeptide-expressing metaplasia), which can progress to intestinal metaplasia — the replacement of stomach lining with intestine-like cells. This metaplastic sequence, combined with the hormonal changes described next, underlies the elevated risk of gastric neuroendocrine tumors (Type 1 carcinoids) and, to a lesser degree, adenocarcinoma. This is why surveillance, not just symptom control, is central to care.

The Clinical Cascade: From Lost Acid to Spinal Cord Damage

The consequences of autoimmune gastritis unfold in a logical, if grim, sequence. Understanding the order matters, because it explains why a person can be quietly sick for years before the dramatic diagnosis of pernicious anemia ever arrives.

Why iron deficiency usually comes first

This is one of the most clinically important and least appreciated facts about autoimmune gastritis. Stomach acid is required to convert dietary non-heme iron from its poorly absorbed ferric (Fe³⁺) form into the absorbable ferrous (Fe²⁺) form, and to liberate iron from food. When achlorhydria sets in, non-heme iron absorption falls sharply. Because the body holds substantial stores of B12 in the liver — often enough for three to five years — but turns over iron far faster, iron deficiency anemia frequently precedes pernicious anemia by years. In fact, autoimmune gastritis is now recognized as a common, under-diagnosed cause of unexplained iron deficiency anemia that does not respond well to oral iron — precisely because the absence of acid blocks oral iron absorption too.

The neurological emergency hidden inside B12 deficiency

When B12 finally runs out, the most feared complication is neurological. Cobalamin is essential for the synthesis of myelin, and its deficiency causes subacute combined degeneration of the spinal cord — a demyelination of the posterior columns (carrying proprioception and vibration sense) and the lateral corticospinal tracts (carrying motor control). Patients lose their sense of where their limbs are in space, develop an unsteady gait, and may progress to weakness and spasticity. Alongside this, B12 deficiency produces peripheral neuropathy (numbness and tingling), cognitive decline (sometimes mistaken for dementia), glossitis (a smooth, sore, beefy-red tongue), and angular stomatitis (cracking at the corners of the mouth). The danger is that neurological damage can become irreversible if B12 is not replaced in time — which is exactly why this disease cannot be managed by hoping a food will fix it.

Neurological manifestations: a severity guide

How Autoimmune Gastritis Is Diagnosed

Because the early disease is silent and the late disease is dangerous, diagnosis hinges on a coordinated panel of blood tests, antibodies, and endoscopy with biopsy. No single test makes the diagnosis; the pattern does.

The hormonal fingerprint: high gastrin, low pepsinogen I

The most elegant biochemical clue lies in a feedback loop. Normally, stomach acid suppresses the antral G cells that secrete gastrin, the hormone that drives acid production. In autoimmune gastritis, achlorhydria removes that negative feedback, so the antrum — which is spared by the disease — pours out gastrin unchecked. The result is a markedly elevated serum gastrin from G-cell hyperplasia. At the same time, destruction of corpus chief cells and parietal cells lowers pepsinogen I, while antral pepsinogen II is relatively preserved, driving the pepsinogen I/II ratio below 3. The triad of high gastrin, low pepsinogen I, and a low pepsinogen I/II ratio is a powerful non-invasive signature of corpus atrophy.

The B12 deficiency biomarker panel

Serum B12 alone can be misleading — it can read falsely normal or borderline. The functional markers are more reliable. When B12 is genuinely deficient, two metabolites that depend on it accumulate: methylmalonic acid (MMA) and homocysteine both rise, because B12 is a cofactor for the enzymes that clear them. Elevated MMA is the most specific functional marker of true cellular B12 deficiency.

The blood film and CBC

The classic hematologic picture of pernicious anemia is megaloblastic anemia: a raised mean corpuscular volume (MCV) with macrocytosis, oval macrocytes on the smear, and hypersegmented neutrophils (six or more lobes). One important trap: if iron deficiency and B12 deficiency coexist — common in this disease — the small red cells of iron deficiency can mask the large cells of B12 deficiency, producing a deceptively normal MCV. This is one more reason the full panel, not a single number, drives the diagnosis.

Endoscopy, biopsy and pH

Definitive diagnosis requires upper endoscopy with biopsies following the updated Sydney protocol — sampling the antrum, corpus, and incisura to map the distribution of atrophy and detect metaplasia or neuroendocrine change. Histology shows corpus-predominant atrophic gastritis with the antrum relatively spared, often with enterochromaffin-like (ECL) cell hyperplasia driven by the high gastrin. Gastric pH monitoring can confirm achlorhydria directly.

The Schilling test — historical context

Older readers may remember the Schilling test, once the classic way to prove B12 malabsorption and localize its cause. It used radiolabeled B12 given with and without intrinsic factor to distinguish intrinsic-factor-related malabsorption (pernicious anemia) from intestinal causes. The test has been largely abandoned in modern practice — radiolabeled reagents became unavailable and antibody testing plus MMA/homocysteine offered a simpler path — but it remains a useful mental model for why the disease causes B12 deficiency: no intrinsic factor, no absorption.

The Company It Keeps: Polyglandular Autoimmunity

Autoimmune gastritis rarely travels alone. It is a frequent member of the autoimmune polyglandular syndrome (APS) type III cluster and shares immunogenetic terrain (HLA-DR3/DR4) with a family of organ-specific autoimmune diseases. A new diagnosis of autoimmune gastritis should prompt screening for these, and a diagnosis of any of them should prompt awareness of gastric autoimmunity.

The grouping known as autoimmune polyglandular syndrome type III specifically pairs autoimmune thyroid disease with other organ-specific autoimmunity (such as autoimmune gastritis or type 1 diabetes) without adrenal involvement. The practical takeaway is simple: if you have autoimmune gastritis, your care team should keep an eye on your thyroid, blood sugar, and — if symptoms warrant — celiac and adrenal status. Our companion page on sea moss for autoimmune disease explores the shared Treg/Th17 biology these conditions have in common.

The H. pylori Question and Achlorhydria's Drug-Absorption Trap

H. pylori can coexist — and matters

Although autoimmune (Type A) gastritis is distinct from Helicobacter pylori (Type B) gastritis, the two can coexist, and there is intriguing evidence that H. pylori infection may act as a trigger that initiates or accelerates autoimmune gastritis in susceptible people through molecular mimicry between bacterial antigens and the H+/K+-ATPase. Current practice is to test for H. pylori in anyone with atrophic gastritis and to treat it if positive; eradication early in the disease course may improve the trajectory in some patients, even though it does not reverse established autoimmune atrophy.

Achlorhydria changes how drugs and nutrients are absorbed

A stomach with no acid is a different chemical environment, and that has real implications:

• Proton pump inhibitors (PPIs) make things worse. PPIs further suppress what little acid remains, deepening malabsorption of iron, B12, calcium, and magnesium. In a patient who already has achlorhydria from autoimmune gastritis, long-term PPI use can compound nutritional deficiencies — a point worth raising with your physician.
• Iron absorption tips. Because oral non-heme iron needs acid, absorption is poor; taking iron with vitamin C (ascorbic acid) can partly compensate by chemically reducing iron, and heme iron (from animal sources) is absorbed by an acid-independent pathway. When oral iron fails — common here — intravenous iron bypasses the gut entirely.
• Zinc and calcium absorption are likewise blunted by the loss of acid, contributing to mucosal, immune, and bone consequences over time.
• Bacterial overgrowth can occur because acid normally sterilizes the upper gut, occasionally adding its own malabsorption.

Carcinoid Surveillance: Why Monitoring Is Non-Negotiable

The chronically high gastrin that defines autoimmune gastritis is not just a diagnostic marker — it is a growth signal. Sustained hypergastrinemia drives proliferation of enterochromaffin-like (ECL) cells in the corpus, and over time this can give rise to Type 1 gastric neuroendocrine tumors (gastric carcinoids). These Type 1 carcinoids are generally indolent and low-risk compared with other neuroendocrine tumors, but they require detection and monitoring, and a minority can behave more aggressively. The metaplastic sequence (SPEM → intestinal metaplasia) also modestly raises the risk of gastric adenocarcinoma.

A practical surveillance protocol

• Endoscopic surveillance every 2–3 years in established autoimmune atrophic gastritis to look for neuroendocrine tumors, intestinal metaplasia, and dysplasia, with biopsies per the Sydney protocol.
• More frequent endoscopy if carcinoids, high-grade metaplasia, or dysplasia are found, individualized by a gastroenterologist.
• Annual laboratory monitoring: B12, iron studies (ferritin, transferrin saturation), serum gastrin, complete blood count, and thyroid function — tracking both the nutritional and the autoimmune dimensions of the disease.

No food, supplement, or sea moss has any role in this surveillance. It is a structured, endoscopy-driven medical program, and it is the part of care that protects against the disease's most serious long-term consequence.

What Standard Medical Treatment Looks Like

There is no cure that reverses the autoimmune destruction of parietal cells, so treatment is built around replacing what the stomach can no longer absorb and monitoring for complications. This is the only honest backdrop for any nutrition discussion.

• Vitamin B12 replacement (the cornerstone for pernicious anemia): Classic therapy is intramuscular cyanocobalamin or hydroxocobalamin, 1000 mcg — typically loading doses followed by maintenance injections every 1–3 months for life. Importantly, high-dose oral B12 (1000–2000 mcg daily) can also be effective because a small fraction (~1%) is absorbed by passive diffusion independent of intrinsic factor — but this only works with strict daily compliance and adequate monitoring, and injections remain standard when neurological symptoms or malabsorption concerns are present.
• Iron repletion: Because oral iron is poorly absorbed in achlorhydria, intravenous iron is often preferred when absorption is compromised. Oral iron with vitamin C may be tried in milder cases.
• Gastric carcinoid surveillance: Endoscopy every 2–3 years as above.
• Annual labs: B12, iron studies, gastrin, CBC, and thyroid function.
• H. pylori testing and eradication if positive, since it can coexist and may worsen the course early on.
• Treat associated autoimmune disease — thyroid, diabetes, celiac — as identified through screening.

What Sea Moss Cannot Do: The B12 Truth

This is the most important section on this page, and it must be unambiguous. Sea moss does not contain bioavailable vitamin B12, and it cannot treat, prevent, or reverse pernicious anemia.

You will sometimes see claims that sea moss or other algae are "rich in B12." This is misleading in a way that can cause real harm. Algae — including sea moss, spirulina, and others — contain pseudovitamin B12 (pseudocobalamin), a corrinoid molecule that looks chemically similar to true cobalamin but is metabolically inactive in humans. Worse, pseudo-B12 can occupy B12 transport and binding sites without delivering any functional benefit, and some researchers have raised concern that it may even interfere with the body's handling of true B12. For a person with autoimmune gastritis — whose entire problem is the inability to absorb B12 — relying on algal "B12" is doubly dangerous: the stomach cannot absorb true B12 without intrinsic factor, and the B12 in the algae was never usable to begin with.

To be equally clear about iron: while sea moss does contain some iron and supplies cofactors, it is not a substitute for medical iron repletion when you are iron-deficient from achlorhydria. If oral iron is not being absorbed, your physician will use intravenous iron. The honest framing throughout this page is that sea moss is a supportive whole food for the gastric mucosa and the inflammatory environment — never a replacement for the two things this disease specifically requires: B12 and iron repletion delivered by routes that work.

Where Sea Moss May Help: Gastric Mucosal Mechanisms

With the boundaries drawn clearly, here is where the nutrients in sea moss genuinely intersect with the biology of the stomach lining and the inflammatory environment of autoimmune gastritis. None of these mechanisms restores parietal cells, supplies B12, or treats the disease — but each touches a pathway relevant to mucosal health and may offer supportive nutrition alongside medical care.

Why the Whole-Food Mineral Matrix Matters Here

Achlorhydria undermines the absorption of several minerals at once — iron, zinc, calcium, and magnesium all depend, to varying degrees, on a normal acid environment. Sea moss delivers roughly 92 minerals in gentle, food-bound, trace amounts. For someone managing autoimmune gastritis, a steady, whole-food supply of cofactors — zinc for mucosal repair, selenium for antioxidant selenoenzymes, magnesium for hundreds of background reactions — supports the tissues and enzymes that a compromised stomach makes harder to nourish.

That said, the very absorption problem that makes mineral intake important also means food alone may not be enough to correct a true deficiency. This is the recurring theme: sea moss is a layer of supportive nutrition on top of, never instead of, the targeted, route-appropriate repletion (often IV iron, always supplemental B12) that this disease specifically requires. Keep your medical team informed of everything you add, especially given the iodine content and the common thyroid overlap.

A Sensible, Doctor-Guided Approach to Sea Moss

If your gastroenterologist agrees sea moss is reasonable for you, keep it simple, conservative, and fully integrated with your medical plan.

Start the conversation first

Bring it up before you begin. Sea moss contains iodine and bioactive fucoidan, and autoimmune gastritis frequently coexists with Hashimoto's thyroiditis, where iodine intake genuinely matters. Your specialist should sign off — especially alongside B12 and iron therapy and any thyroid medication.

Modest, consistent servings

A typical serving is 1–2 tablespoons of sea moss gel daily. With iodine, consistency at a moderate dose beats large amounts — more is not better. Stir it into a smoothie, oats, or a drink alongside a meal, where its mucilaginous, soothing texture is easiest on the stomach.

Never let it replace your essentials

Keep every appointment, every blood draw, and every B12 injection or dose. Sea moss does not change your need for B12 replacement, iron repletion, or endoscopic surveillance, and it supplies no usable B12. Watch for warning signs — numbness or tingling, balance problems, a sore smooth tongue, breathlessness, or worsening fatigue — and act on them immediately. Support nutrition; let your medical team treat the disease.